HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LMB-11

a variant of moxetumomab pasudotox that targets CD22 for treatment of hairy cell leukemia

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 2472
- Biological Toxins: 20
  - Bacterial Toxins: 814
    - LMB-11: 1
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Immunoglobulin Variable Region: 208
        LMB-11: 1
        Immunoglobulin Variable Region: 208
        LMB-11: 1
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Immunoglobulin Variable Region: 208
        LMB-11: 1
        Immunoglobulin Variable Region: 208
        LMB-11: 1
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Immunoglobulin Variable Region: 208
        LMB-11: 1
        Immunoglobulin Variable Region: 208
        LMB-11: 1
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fab Fragments: 769
        Immunoglobulin Variable Region: 208
        LMB-11: 1
Chemical Phenomena
- Biochemical Phenomena
  - Molecular Structure
    - Amino Acid Sequence
      - Immunoglobulin Variable Region: 208
        LMB-11: 1

Experts

1.	Liu, Xiufen: 1 article (01/2016)
2.	Müller, Fabian: 1 article (01/2016)
3.	Pastan, Ira: 1 article (01/2016)
4.	Wayne, Alan S: 1 article (01/2016)

Related Diseases

1.

Burkitt Lymphoma (Burkitt's Lymphoma)

01/01/2016 - "LMB-11 is an improved variant of HA22 with reduced immunogenicity, has a longer half-life in the blood and high activity in vitro and in a Burkitt lymphoma model in vivo Searching for RIT enhancing combination therapies, we found the protein kinase A inhibitor H89 to enhance LMB-11 and HA22 activity 5- to 10-fold on ALL cell lines and on patient-derived ALL samples. "

Related Drugs and Biologics

1.	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)

Related Therapies and Procedures

1.	Therapeutics